AlphAIAlphAI — Financial news for AI agents
yahoo.comSEP 232 min read$AMGN

First of Amgen’s Phase III Sjögren’s disease trials succeeds

Amgen's Phase III trial for dazodalibep in Sjögren's disease met its primary endpoint, showing a significant reduction in disease activity. The drug, acquired via Horizon Therapeutics, is being studied in another Phase III trial. No FDA-approved treatments exist for Sjögren's disease. Amgen plans to present detailed data at a medical meeting. Competitors like Novartis, RemeGen, and Johnson & Johnson are also developing treatments.

Original reporting
yahoo.com
Published Sep 23, 2026, 4:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 5:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
First of Amgen’s Phase III Sjögren’s disease trials succeeds — source image
Source · yahoo.com
Decision brief

The 30-second read

$AMGNBullishMed
01

Why it matters

Positive trial data may accelerate FDA filing and increase Amgen's valuation in the autoimmune space.

02

Market read

First pivotal data for a novel autoimmune indication; likely to move Amgen stock and influence sector sentiment.

03

What to watch

Potential competition from Novartis and other pipeline candidates could limit Amgen's market share.

Relevance 9/10Novelty 9/10Timing: today

Background

Amgen acquired the drug candidate in its $27.8bn Horizon Therapeutics buyout; no approved treatments exist for Sjögren's disease.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

Amgen's Phase III trial of dazodalibep met its primary endpoint, a first positive pivotal result for Sjögren's disease.

Expected impact

Potential short-term rally of 5-10% on news, with longer-term upside if regulatory filing proceeds.

Evidence & confidence

First-in-class trial success is material for a large biotech; market typically reacts strongly to pivotal data.

Market effects

Sector

Boosts biotech sector sentiment on autoimmune therapeutics and may lift peers developing similar drugs.

Regional

U.S. biotech market gains confidence; limited immediate global effect.

Global

Highlights continued pipeline strength of large-cap US biotech firms.

Counterpoint

What could challenge this read

Skeptics may argue that regulatory approval is still uncertain and market may have priced in optimism.

Key entities

  • Company
    Amgen

    Biotech firm reporting trial success.

Read at source← All news

Also covered by

4 outlets

Related articles

SEP 24
$NVOMed

GLP-1 prices are falling but a big change could affect what you pay

Novo Nordisk will cut U.S. list prices for Ozempic and Wegovy by 34% and 50% respectively, starting in 2027. Eli Lilly's new GLP-1 pill, Foundayo, was approved by the FDA. Prices vary by insurance coverage. Some employers, like PepsiCo and Cigna, are ending weight loss drug coverage. New drugs from Lilly, Novo Nordisk, and Amgen are in development.

nbcdfw.com3 min
SEP 23
$AMGNHighAI 9/10

AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study

Amgen (AMGN) reported positive phase III study results for dazodalibep in systemic Sjögren's disease, showing significant improvement in disease activity. The company plans to present detailed data at an upcoming conference. AMGN shares have risen 27.9% year-to-date. Other pipeline candidates include olpasiran, xaluritamig, and daxdilimab.

finance.yahoo.com2 min
SEP 23
$AMGNMedAI 8/10

Canaccord reiterates Amgen stock Hold rating on pipeline win

Canaccord Genuity reiterated a Hold rating and $384 price target for Amgen (AMGN) after positive Phase 3 trial results for dazodalibep. The drug showed significant improvement in treating moderate-to-severe Sjogren’s disease. Amgen's stock trades at $410.24, with a P/E ratio of 25.46 and PEG ratio of 0.79. Analysts have mixed reactions, with some raising targets and others downgrading.

investing.com2 min
SEP 23
$AMGNHighAI 9/10

Amgen's Horizon buyout delivers Sjögren's disease win

Amgen's dazodalibep showed efficacy in a phase 3 trial for Sjögren's disease, meeting its primary endpoint. The drug is part of Amgen's $28B Horizon Pharma acquisition. Full data from a second trial is expected by year-end. No FDA-approved treatments exist for this autoimmune disorder.

pharmaphorum.com2 min
SEP 23
$AMGNHighAI 8/10

Amgen (AMGN) Following Its Sjögren's Trial Win Through A Valuation Lens

Amgen (AMGN) reported positive Phase 3 trial results for dazodalibep in treating Sjögren's disease. The stock has gained 25.21% YTD and 47% over 1 year. Analysts debate its valuation, with some arguing it's 14% overvalued at $410.24, while a DCF model suggests it's undervalued at $669.25. The company's pipeline and debt levels are key considerations.

simplywall.st3 min